- Home
- HHS vs VYNE Comparison
HHS vs VYNE Comparison
Compare HHS & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- VYNE
- Stock Information
- Founded
- HHS 1923
- VYNE 2003
- Country
- HHS United States
- VYNE United States
- Employees
- HHS N/A
- VYNE N/A
- Industry
- HHS Advertising
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- VYNE Health Care
- Exchange
- HHS Nasdaq
- VYNE Nasdaq
- Market Cap
- HHS 39.4M
- VYNE 35.7M
- IPO Year
- HHS N/A
- VYNE 2018
- Fundamental
- Price
- HHS $5.05
- VYNE $2.74
- Analyst Decision
- HHS
- VYNE Strong Buy
- Analyst Count
- HHS 0
- VYNE 2
- Target Price
- HHS N/A
- VYNE $6.88
- AVG Volume (30 Days)
- HHS 17.7K
- VYNE 84.7K
- Earning Date
- HHS 03-13-2025
- VYNE 02-27-2025
- Dividend Yield
- HHS N/A
- VYNE N/A
- EPS Growth
- HHS N/A
- VYNE N/A
- EPS
- HHS N/A
- VYNE N/A
- Revenue
- HHS $187,604,000.00
- VYNE $493,000.00
- Revenue This Year
- HHS N/A
- VYNE $28.30
- Revenue Next Year
- HHS $4.05
- VYNE N/A
- P/E Ratio
- HHS N/A
- VYNE N/A
- Revenue Growth
- HHS N/A
- VYNE 39.27
- 52 Week Low
- HHS $4.85
- VYNE $1.57
- 52 Week High
- HHS $8.87
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- HHS 38.02
- VYNE 56.12
- Support Level
- HHS $5.31
- VYNE $2.39
- Resistance Level
- HHS $5.33
- VYNE $2.65
- Average True Range (ATR)
- HHS 0.19
- VYNE 0.20
- MACD
- HHS -0.02
- VYNE 0.05
- Stochastic Oscillator
- HHS 9.26
- VYNE 71.01
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.